Our Research Trials

Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients  with Clinically Evident Cardiovascular Disease.
Sponsored by AMGEN – 2016 to present.   Dr. Richard Rothschild, Principal Investigator

“GOULD Registry” – Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): A Registry of High Cardiovascular Risk Subjects in the United States.
Sponsored by AMGEN – 2016 to present.  Dr. Richard Rothschild, Principal Investigator

“FOURIER Trial” – A Double-blind, Randomized, Placebo-controlled Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 Is Used With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease.
Sponsored by AMGEN – 2013 to present.  Dr. Richard Rothschild, Principal Investigator & Dr. David Schmidt, Sub-Investigator

Aastrom/Vericel  – An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)
Dr. David Schmidt, Principal Investigator & Dr. Richard Rothschild, Sub-Investigator

“PreSERVE Study” – A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intracoronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product in Patients with Acute Myocardial Infarction.
Sponsored by Amorcyte – 2012.  Dr. Richard Rothschild, Principal Investigator & Dr. David Schmidt, Sub-Investigator.

“Renew Study” – A Prospective, Randomized, Double-Blinded, Active-Control and Unblinded Standard of Care (SOC) Controlled Study to Determine the Efficacy and Safety of Targeted Intramyocardial Delivery of G-CSF Mobilized Autologous CD34+Cells for the Improvement on Total Exercise Time During Standardized Exercise Testing in Subjects with Refractory Angina Pectoris and Chronic Myocardial Ischemia (CMI).
Sponsored by Baxter Health Corporation – 2012.   Dr. Richard Rothschild, Sub-Investigator & Dr. David Schmidt, Sub-Investigator

Teva/Mesoblast – Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.
Dr. Richard Rothschild, Principal Investigator & Dr. David Schmidt, Sub-Investigator